SCHEMBL1447675

SCHEMBL1447675

CC(=O)C=Cc1ccccc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.63
▸ LMNA P02545 5/20 0.63
▸ HDAC1 Q13547 1/20 0.62
▸ HDAC8 Q9BY41 1/20 0.62
▸ HDAC6 Q9UBN7 1/20 0.62
▸ GSR P00390 1/20 0.62
▸ KDM4E B2RXH2 2/20 0.58
▸ MAOB P27338 3/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ HSP90AA1 P07900 1/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ HPGD P15428 1/20 0.55
▸ IAPP P10997 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ CYP1A1 P04798 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447672 1.00 MAPT (0.63) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL31356685 1.00 MAPT (0.63) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL14441077 0.85 MAPT (0.76) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL31553473 0.83 GSR (0.79) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL22596712 0.83 HDAC1 (0.67) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL2744240 0.83 GSR (0.79) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL30468232 0.83 GSR (0.79) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL2744242 0.83 GSR (0.79) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL1404763 0.83 IAPP (0.69) MAPTLMNAHDAC1HDAC8HDAC6
SCHEMBL1404762 0.83 IAPP (0.69) MAPTLMNAHDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4643805-A CONTAINING UNSATURATED OXO PYRIDINE, AROMATIC, FURAN, OR THIOPHENE COMPOUND POPESCU FRANCINE (FR) 1987-02-17 — — US claimed
CN-122038326-A Perakine reductase mutant and application thereof in double bond reduction 浙江大学 2026-05-15 — — CN disclosed
EP-3930849-B1 THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2025-02-19 — — EP disclosed
CN-115232019-B Synthesis method of 3-acetamido benzotrifluoride compound 闽江学院 2023-10-27 — — CN disclosed
CN-115232019-A Synthetic method of 3-acetamido benzotrifluoride compound 闽江学院 2022-10-25 — — CN disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 — — US disclosed
CN-113993587-A Thiazole derivatives as protein secretion inhibitors 科智生命科学公司 2022-01-28 — — CN disclosed
CN-107922324-B Beta-naphthol ether sulfonates, process for their preparation and their use as brightness improvers 巴斯夫欧洲公司 2021-02-02 — — CN disclosed
EP-3297986-B1 BETA NAPHTHOLETHER SULFONATES, METHOD FOR THEIR PREPARATION AND THEIR USE AS GLOSS IMPROVERS BASF SE (DE) 2019-07-10 — — EP disclosed
WO-2015101928-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-09 — — WO disclosed
EP-0071819-B1 DIHYDROPYRIDINES WITH A POSITIVE INOTROPIC ACTIVITY, THEIR USE IN PHARMACEUTICAL PREPARATIONS, AND PROCESSES FOR THEIR PREPARATION BAYER AG (DE) 1987-04-22 — — EP disclosed
US-4643805-A CONTAINING UNSATURATED OXO PYRIDINE, AROMATIC, FURAN, OR THIOPHENE COMPOUND POPESCU FRANCINE (FR) 1987-02-17 — — US disclosed
US-4532248-A Administering 1,4-dihydropyridine derivative exhibiting positive inotropic activity BAYER AKTIENGESELLSCHAFT (DE) 1985-07-30 — — US disclosed
EP-0071819-A1 Dihydropyridines with a positive inotropic activity, their use in pharmaceutical preparations, and processes for their preparation BAYER AG (DE) 1983-02-16 — — EP disclosed
EP-0004624-B1 CHROMANON DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICINES AND GROWTH-PROMOTING AGENTS BAYER AG (DE) 1982-02-24 — — EP disclosed
US-4288456-A Compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and method for treating inflammatory conditions E. R. SQUIBB & SONS, INC. (US) 1981-09-08 — — US disclosed
US-4261988-A ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY BAYER AKTIENGESELLSCHAFT (DE) 1981-04-14 — — US disclosed
US-4173649-A ANTIULCER AGENTS E. R. SQUIBB & SONS, INC. (US) 1979-11-06 — — US disclosed
EP-0004624-A2 Chromanon derivatives, process for their preparation, and their use as medicines and growth-promoting agents BAYER AG (DE) 1979-10-17 — — EP disclosed
US-3989708-A HYPOTENSIVE, CORONARY VESSEL DILATORS BAYER AKTIENGESELLSCHAFT (DT) 1976-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G MAPT 2487/4885LMNA 3715/4885HDAC1 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback